Global, regional, and national burden of inflammatory bowel disease, 1990-2021: Insights from the global burden of disease 2021.
Epidemiology
Global Burden of Diseases
Inflammatory bowel disease
Journal
International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899
Informations de publication
Date de publication:
07 Sep 2024
07 Sep 2024
Historique:
accepted:
28
08
2024
medline:
7
9
2024
pubmed:
7
9
2024
entrez:
7
9
2024
Statut:
epublish
Résumé
The prevalence of inflammatory bowel disease (IBD) is on the rise worldwide. We utilizes data from the Global Burden of Diseases (GBD) 2021 to analyze the national-level burden of IBD, trends in disease incidence, and epidemiological characteristics. Detailed information on IBD was gathered from 204 countries and territories spanning 1990 to 2021, sourced from the GBD 2021. Calculations were performed for incidence rates, mortality rates, disease-adjusted life years (DALYs), and estimated annual percentage changes (EAPCs). These trends were analyzed based on region, nationality, age, gender, and World Bank income level stratifications. The global age-standardised incident rate (ASIR) of IBD increased from 4.22 per 100000 in 1990 to 4.45 per 100000 in 2021. However, the age-standardised mortality rate (ASMR) decreased from 0.60 per 100000 in 1990 to 0.52 per 100000 in 2021. Similarly, the age-standardised DALYs rate decreased from 21.55 per 100000 in 1990 to 18.07 per 100000 in 2021. Gender comparisons showed negligible differences in disease burden. The greatest increase in IBD-associated ASIR and ASMR occurred in World Bank upper-middle income region (EAPCs, 1.25) and World Bank high-income region (EAPCs, 1.00), respectively. Regionally, East Asia experienced the largest increase in ASIR (EAPCs, 2.89). Among 204 countries, China had the greatest increases in ASIR (EAPCs, 2.93), Netherlands had the highest ASMR in 2021 (2.21 per 100000). Global incidence rate of IBD have been increasing from 1990 to 2021, while the DALYs and mortality have been decreasing. The escalating incident rates in select Asian regions deserves further attention.
Identifiants
pubmed: 39243331
doi: 10.1007/s00384-024-04711-x
pii: 10.1007/s00384-024-04711-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
139Subventions
Organisme : Zhejiang Provincial Natural Science Foundation
ID : LY23H030004
Informations de copyright
© 2024. The Author(s).
Références
Kang SG, Gweon TG, Lee HH et al (2022) Reliability and validity of Korean version of crohn’s and ulcerative colitis questionnaire-8. Biomed Res Int 2022(7):9746899
pubmed: 36246964
pmcid: 9568317
Xu YH, Zhu WM, Guo Z (2022) Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease. World J Gastroenterol 28(48):6888–6899
doi: 10.3748/wjg.v28.i48.6888
pubmed: 36632311
pmcid: 9827580
GBD 2017 Inflammatory Bowel Disease Collaborators (2020) The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 5(1):17–30
doi: 10.1016/S2468-1253(19)30333-4
Cantoro L, Monterubbianesi R, Falasco G et al (2023) The earlier you find, the better you treat: red flags for early diagnosis of inflammatory bowel disease. Diagnostics (Basel) 13(20):3183
doi: 10.3390/diagnostics13203183
pubmed: 37892004
Noble AJ, Nowak JK, Adams AT et al (2023) Defining interactions between the genome, epigenome, and the environment in inflammatory bowel disease: progress and prospects. Gastroenterology 165(1):44-60.e2
doi: 10.1053/j.gastro.2023.03.238
pubmed: 37062395
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1789–1858
doi: 10.1016/S0140-6736(18)32279-7
GBD 2017 Causes of Death Collaborators (2018) Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10160):2170
Murray CJ, Lopez AD (1996) Evidence-based health policy lessons from the Global Burden of Disease Study. Science 274:740–743
doi: 10.1126/science.274.5288.740
pubmed: 8966556
Zhang Y, Liu J, Han X et al (2022) Long-term trends in the burden of inflammatory bowel disease in China over three decades: A joinpoint regression and age-period-cohort analysis based on GBD 2019. Front Public Health 7(10):994619
doi: 10.3389/fpubh.2022.994619
Kaplan GG, Windsor JW (2021) The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 18(1):56–66
doi: 10.1038/s41575-020-00360-x
pubmed: 33033392
Harbord M, Eliakim R, Bettenworth D et al (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 11(7):769–784
doi: 10.1093/ecco-jcc/jjx009
pubmed: 28513805
Travis SP, Stange EF, Lémann M et al (2006) European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 55(Suppl 1):i16-35
doi: 10.1136/gut.2005.081950b
pubmed: 16481629
pmcid: 1859997
Qiu Y, Ren W, Liu Y et al (2020) Disease burden of inflammatory bowel disease in China from 1990 to 2017: Findings from the global burden of diseases 2017. EClinicalMedicine 20(27):100544
doi: 10.1016/j.eclinm.2020.100544
Cao F, He YS, Wang Y et al (2023) Global burden and cross-country inequalities in autoimmune diseases from 1990 to 2019. Autoimmun Rev 22(6):103326
doi: 10.1016/j.autrev.2023.103326
pubmed: 36958621
Law ST, Li KK (2014) Gender-related differences in clinical course of crohn’s disease in an Asian population: a retrospective cohort review. Arq Gastroenterol 51(2):90–96
doi: 10.1590/S0004-28032014000200004
pubmed: 25003258
Wu R, Xiong R, Li Y et al (2023) Gut microbiome, metabolome, host immunity associated with inflammatory bowel disease and intervention of fecal microbiota transplantation. J Autoimmun 141:103062
doi: 10.1016/j.jaut.2023.103062
pubmed: 37246133
Gilliland A, Chan JJ, De Wolfe TJ et al (2024) Pathobionts in inflammatory bowel disease: origins, underlying mechanisms, and implications for clinical care. Gastroenterology 166(1):44–58
doi: 10.1053/j.gastro.2023.09.019
pubmed: 37734419
Suez J, Korem T, Zeevi D et al (2014) Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature 514(7521):181–186
doi: 10.1038/nature13793
pubmed: 25231862
Ananthakrishnan AN, Khalili H, Konijeti GG et al (2013) A prospective study of long-term intake of dietary fiber and risk of Crohn’s disease and ulcerative colitis. Gastroenterology 145(5):970–977
doi: 10.1053/j.gastro.2013.07.050
pubmed: 23912083
Ng SC, Tang W, Leong RW et al (2015) Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut 64(7):1063–1071
doi: 10.1136/gutjnl-2014-307410
pubmed: 25217388
Piovani D, Danese S, Peyrin-Biroulet L et al (2020) Environmental, nutritional, and socioeconomic determinants of IBD incidence: a global ecological study. J Crohns Colitis 14(3):323–331
doi: 10.1093/ecco-jcc/jjz150
pubmed: 31504350
Chan JC, Malik V, Jia W et al (2009) Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301(20):2129–2140
doi: 10.1001/jama.2009.726
pubmed: 19470990
Meng Q, Fang H, Liu X et al (2015) Consolidating the social health insurance schemes in China: towards an equitable and efficient health system. Lancet 386(10002):1484–92
doi: 10.1016/S0140-6736(15)00342-6
pubmed: 26466052
Chen Y (2018) Perspectives of IBD China: Is Crohn’s and Colitis Foundation Model a Solution to Health Care Issues for the Country? Inflamm Bowel Dis 24(5):925–929
doi: 10.1093/ibd/izy056
pubmed: 29688396
GBD 2017 Mortality Collaborators (2018) Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159):1684–1735
doi: 10.1016/S0140-6736(18)31891-9